NEWS

  • MPN RESEARCH PAYS OFF AS NEW MPN DRUGS ADVANCE TO MARKET: A REPORT FROM ASCO

    June 2011 June’s American Society of Clinical Oncology (ASCO) conference in Chicago demonstrated that investments in MPN Research are starting to pay off as multiple drugs move through the drug development pipeline. Walking the halls of McCormick one could not help but be struck by strong notes of excitement and optimism. Discoveries related to melanoma,… Read More »MPN RESEARCH PAYS OFF AS NEW MPN DRUGS ADVANCE TO MARKET: A REPORT FROM ASCO

    READ MORE

    PATIENTS PUSH RESEARCHERS TO SHARE DATA

    March 2011 The patients who run the MPD Foundation are impatient to see results from the medical research they fund. That’s understandable: their rare blood diseases – essential thrombocythemia, polycythemia vera and myelofibrosis, collectively called myeloproliferative neoplasms – are progressive, incurable and generally not well managed by existing medicines. So, in its latest round of… Read More »PATIENTS PUSH RESEARCHERS TO SHARE DATA

    READ MORE

    EUROPEAN JOURNAL OFFERS REVIEW OF CURRENT JAK INHIBITORS

    April 2011 The Belgian Journal of Hematology recently published their review of the state of JAK Inhibitors. Since its discovery in 2005 several companies have been working on creating a JAK Inhibitor for treatment of the myeloproliferative neoplasms. Click here to read the full article (PDF) Current trials for polycythemia vera, essential thrombocythemia and myelofibrosis… Read More »EUROPEAN JOURNAL OFFERS REVIEW OF CURRENT JAK INHIBITORS

    READ MORE

    GERON ENROLLS FIRST PATIENT IN DRUG STUDY FOR ESSENTIAL THROMBOCYTHEMIA

    January 2011 Geron Corporation has enrolled their first person in a Phase 2 clinical trial to test their drug (GRN163L) in patients with essential thrombocythemia. These drugs are aiming to target the leukemic stem cell, which Geron believes will “impact the biology of the disease”. This Phase 2 trial is testing the safety and efficacy… Read More »GERON ENROLLS FIRST PATIENT IN DRUG STUDY FOR ESSENTIAL THROMBOCYTHEMIA

    READ MORE

    ASCO RELEASES VIDEOS OF EXPERTS DISCUSSING MPDS

    December 2010 The American Society of Clinical Oncology (ASCO) recently released three videos of renowned MPD specialists discussing various topics related to MPDs. Drs. Ayalew Tefferi, William Vainchencker and James Vardiman contributed to the series. Click here to view videos

    READ MORE

    MPD CHAT ARCHIVES ASH ABSTRACTS

    December 2010 Online chat and support group MPD-Chat has listed all abstracts presented at the recent American Society of Hematology meeting that are relevant to MPD/MPN. Take a look at the abstract as well as the discussion boards. Thanks to MPD Chat for compiling this list!

    READ MORE

    SBIO DRUG SHOWS PROMISE FOR SYMPTOM AND SPLEEN REDUCTION FOR MYELOFIBROSIS PATIENTS

    December 2010 Data from SBio’s ongoing clinical trial for their JAK2 Inhibitor SB1518 was reported at the recent annual meeting of the American Society of Hematology. Dr. Srdan Verstovsek reported that thus far 57% of patients enrolled had experience reduction in spleen as well as reduction in constitutional symptoms of myelofibrosis. The drug was reported… Read More »SBIO DRUG SHOWS PROMISE FOR SYMPTOM AND SPLEEN REDUCTION FOR MYELOFIBROSIS PATIENTS

    READ MORE

    INCYTE REPORTS POSITIVE RESULTS OF JAK INHIBITOR TESTED IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA PATIENTS

    December 2010 Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424. These trials are testing safety and efficacy of this drug, meant to relieve constitutional symptoms in ET and PV patients. Results were reported at the American Society of Hematology’s annual meeting. Click here for more information

    READ MORE

    MPD DOCTORS DISCUSS BENEFITS OF 2 JAK2 INHIBITORS

    December 2010 Drs. Ayalew Tefferi and Animesh Pardanani presented data at ASH on the benefits of two drugs currently in clinical trials: TG101348 and CYT387. TG101348 is currently being tested in myelofibrosis patients and has been shown to reduce constitutional symptoms as well as reduction in spleen size and JAK burden in many of the… Read More »MPD DOCTORS DISCUSS BENEFITS OF 2 JAK2 INHIBITORS

    READ MORE

    SBIO GRANTED ORPHAN DESIGNATION FOR MYELOFIBROSIS DRUG

    October 2010 SBio, based in Singapore, is working on a JAK2 Inhibitor for Myelofibrosis patients, SB1518. They have just been granted orphan drug designation from the European Commission. The European Commission is the executive body of the European Union, and has an orphan drug incentive program similar to the U.S. This development potentially expands the… Read More »SBIO GRANTED ORPHAN DESIGNATION FOR MYELOFIBROSIS DRUG

    READ MORE

    1 2 3 4 37
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?